Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria

FEMS Immunology and Medical Microbiology

Volumn 48, Issue 3, 2006, Pages 381-389

  Lee, Kyung Yeol ^b   Kim, Dong Heon ^b   Kang, Tae Jin ^b   Kim, Ju ^b   Chung, Gook Hyun ^b   Yoo, Han Sang ^c   Arntzen, Charles J ^d   Yang, Moon Sik ^b   Jang, Yong Suk ^a,b  

^a Chonbuk National University ^*  (South Korea)

^b Chonbuk National University   (South Korea)

^c Seoul National University   (South Korea)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Actinobacillus pleuropneumoniae; Edible vaccine; Transgenic plant

Indexed keywords

EXOTOXIN;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNOGENICITY; KOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE;

ACTINOBACILLUS INFECTIONS; ACTINOBACILLUS PLEUROPNEUMONIAE; ADMINISTRATION, ORAL; ANIMALS; BACTERIAL PROTEINS; DISEASE MODELS, ANIMAL; EXOTOXINS; HEMOLYSIN PROTEINS; MICE; PLANTS, GENETICALLY MODIFIED; TOBACCO; VACCINES; VACCINES, SYNTHETIC;

EID: 33750942121     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2006.00158.x     Document Type: Article

References (46)

1. Anderson C, Potter AA & Gerlach GF (1991) Isolation and molecular characterization of spontaneously occurring cytolysin-negative mutants of Actinobacillus pleuropneumoniae serotype 7. Infect Immun 59: 4110-4116.
2. Bae J-L, Lee J-G, Kang T-J, Jang H-S, Jang Y-S & Yang M-S (2003) Induction of antigen-specific systemic and mucosal immune responses by feeding animals transgenic plants expressing the antigen. Vaccine 21: 4052-4058.
3. Boekema BK, Kamp EM, Smits MA, Smith HE & Stockhofe-Zurwieden N (2004) Both ApxI and ApxII of Actinobacillus pleuropneumoniae serotype 1 are necessary for full virulence. Vet Microbiol 100: 17-23.
4. Bosse JT, Janson H, Sheehan BJ, Beddek AJ, Rycroft AN, Kroll JS & Langford PR (2002) Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microb Infect 4: 225-235.
5. Canizares MC, Nicholson L & Lomonossoff GP (2005) Use of viral vectors for vaccine production in plants. Immunol Cell Biol 83: 263-270.
6. Daniell H, Khan MS & Allison L (2002) Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci 7: 84-91.
7. Dong J-L, Liang B-G, Jin Y-S, Zhang W-J & Wang T (2005) Oral immunization with pBs VP6-transgenic alfalfa protects mice against rotavirus infection. Virology 339: 153-163.
8. Dubreuil JD, Jacques M, Mittal KR & Gottschalk M (2000) Actinobacillus pleuropneumoniae surface polysaccharides: their role in diagnosis and immunogenicity. Anim Health Res Rev 1: 73-93.
9. Frey J (1995) Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends Microbiol 3: 257-261.
10. Fujihashi K, Kato H, van Ginkel FW et al. (2001) A revisit of mucosal IgA immunity and oral tolerance. Acta Odontol Scand 59: 301-308.
11. Fuller TE, Martin S, Teel JF, Alaniz GR, Kennedy MJ & Lowery DE (2000) Identification of Actinobacillus pleuropneumoniae virulence genes using signature-tagged mutagenesis in a swine infection model. Microb Pathol 29: 39-51.
12. Haesebrouck F, Chiers K, Van Overbeke I & Ducatelle R (1997) Actinobacillus pleuropneumoniae infections in pigs: the role of virulence factors in pathogenesis and protection. Vet Microbiol 58: 239-249.
13. Haesebrouck F, Pasmans F, Chiers K, Maes D, Ducatelle R & Decostere A (2004) Efficacy of vaccines against bacterial diseases in swine: what can we expect? Vet Microbiol 100: 255-268.
14. Hensel A, van Leengoed LA, Szostak M et al. (1996) Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J Biotechnol 44: 171-181.
15. Jarma E & Regassa LB (2004) Growth phase mediated regulation of the Actinobacillus pleuropneumoniae ApxI and ApxII toxins. Microb Pathol 36: 197-203.
16. Jarma E, Corradino G & Regassa LB (2004) Anaerobiosis, growth phase and Actinobacillus pleuropneumoniae RTX toxin production. Microb Pathol 37: 29-33.
17. Kamp EM, Popma JK, Anakotta J & Smits MA (1991) Identification of hemolytic and cytotoxic proteins of Actinobacillus pleuropneumoniae by use of monoclonal antibodies. Infect Immun 59: 3079-3085.
18. Kang T-J & Yang M-S (2004) Rapid and reliable extraction of genomic DNA from various wild-type and transgenic plants. MBC Biotechnol 4: 20.
19. Kim S-H, Lee K-Y, Kim J, Park S-M, Park BK & Jang Y-S (2006) Identification of a peptide motif enhancing mucosal and systemic immune responses against the peptide conjugated-antigen after oral administration in mice. Mol Cells 21: 244-250.
20. Lally ET, Hill RB, Kieba IR & Korostoff J (1999) The interaction between RTX toxins and target cells. Trends Microbiol 7: 356-361.
21. Lauterslager TG & Hilgers LA (2002) Efficacy of oral administration and oral intake of edible vaccines. Immunol Lett 84: 185-190.
22. Lee J-H, Kim N-S, Kwon T-H, Jang Y-S & Yang M-S (2002) Increased production of human granulocyte-macrophage colony stimulating factor (hGM-CSF) by the addition of stabilizing polymer in plant suspension cultures. J Biotechnol 96: 205-211.
23. Lenser DK, McDonald TL & Miller NG (1988) Protection of mice against the lethal effect of an intraperitoneal infection with Haemophilus (Actinobacillus) pleuropneumoniae after vaccination with capsular proteins. Vet Microbiol 18: 335-348.
24. Liang W, Huang Y, Yang X, Zhou Z, Pan A, Qian B, Huang C, Chen J & Zhang D (2005) Oral immunization of mice with plant-derived fimbrial adhesin FaeG induces systemic and mucosal K88ad enterotoxigenic Escherichia coli-specific immune responses. FEMS Immunol Med Microbiol 46: 393-399.
25. Maier E, Reinhard N, Benz R & Frey J (1996) Channel-forming activity and channel size of the RTX toxins ApxI, ApxII, and ApxIII of Actinobacillus pleuropneumoniae. Infect Immun 64: 4415-4423.
26. Mason HS, Warzecha H, Mor T & Arntzen CJ (2002) Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 8: 324-329.
27. Mercenier A, Wiedermann U & Breiteneder H (2001) Edible genetically modified microorganisms and plants for improved health. Curr Opin Biotechnol 12: 510-515.
28. Min K & Chae C (1999) Serotype and apx genotype profiles of Actinobacillus pleuropneumoniae field isolates in Korea. Vet Res 145: 251-254.
29. Modelska A, Dietzschold B, Sleysh N, Fu ZF, Steplewski K, Hooper DC, Koprowski H & Yusibov V (1998) Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci USA 95: 2481-2485.
30. Molina A, Veramendi J & Hervás-Stubbs S (2005) Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus. Virology 342: 266-275.
31. Montaraz JA, Rosales ME, Bautista E, Barcenas G & Lara V (1994) A novel experimental model for the study and evaluation of experimental vaccines to Actinobacillus pleuropneumoniae. Vet Immunol Immunopathol 41: 375-380.
32. Ogra PL, Faden H & Welliver RC (2001) Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14: 430-445.
33. Prideaux CT, Pierce L, Krywult J & Hodgson AL (1998) Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Curr Microbiol 37: 324-332.
34. Prideaux CT, Lenghaus C, Krywult J & Hodgson AL (1999) Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon. Infect Immun 67: 1962-1966.
35. Reimer D, Frey J, Jansen R, Veit HP & Inzana TJ (1995)Molecular investigation of the role of ApxI and ApxII in the virulence of Actinobacillus pleuropneumoniae serotype 5. Microb Pathol 18: 197-209.
36. Richter LJ, Thanavala Y, Arntzen CJ & Mason HS (2000) Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 18: 1167-1171.
37. Rigano MM, Dreitz S, Kipnis A-P, Izzo AA & Walmsley AM (2006) Oral immunogenicity of a plant-made, subunit, tuberculosis vaccine. Vaccine 24: 691-695.
38. Seah JN, Frey J & Kwang J (2002) The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice. Infect Immun 70: 6464-6467.
39. Shin SJ, Bae JL, Cho Y-W, Lee DY, Kim D-H, Yang M-S, Jang Y-S & Yoo HS (2005a) Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol Microbiol 43: 155-164.
40. Shin SJ, Cho YW & Yoo HS (2005b) Cloning, sequencing and expression of apxIA, IIA, IIIA of Actinobacillus pleuropneumoniae isolated in Korea. Korean J Vet Res 43: 247-253.
41. Tacket CO & Mason HS (1999) A review of oral vaccination with transgenic vegetables. Microbes Infect 1: 777-783.
42. Tascon RI, Vazquez-Boland JA, Gutierrez-Martin CB, Rodriguez-Barbosa I & Rodriguez-Ferri EF (1994) The RTX haemolysin ApxI and ApxII are major virulence factors of the swine pathogen Actinobacillus pleuropneumoniae: evidence from mutational analysis. Mol Microbiol 14: 207-216.
43. Tonpitak W, Baltes N, Hennig-Pauka I & Gerlach GF (2002) Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine. Infect Immun 70: 7120-7125.
44. Walmsley AM & Arntzen CJ (2003) Plant cell factories and mucosal vaccines. Curr Opin Biotechnol 14: 145-150.
45. Warzecha H, Mason HS, Lane C, Tryggvesson A, Rybicki E, Williamson AL, Clements JD & Rose RC (2003) Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 77: 8702-8711.
46. Yuki Y & Kiyono H (2003) New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 13: 293-310.